|
Toxicities (RTOG Grade)
|
h-R3/RT (N = 13) [n (%)]
|
CDDP/RT (N = 13) [n (%)]
|
P Value*
|
|---|
|
WBC
| | |
0.711
|
|
(1&2)
|
10 (76.9%)
|
6 (46.2%)
| |
|
(3&4)
|
0 (0.0%)
|
3 (23.1%)
| |
|
PLT
| | |
0.380
|
|
(1&2)
|
6 (46.2%)
|
6 (46.2%)
| |
|
(3&4)
|
0 (0.00%)
|
1 (7.7%)
| |
|
HB
| | |
0.083
|
|
(1&2)
|
8 (61.5%)
|
5 (61.5%)
| |
|
(3&4)
|
0 (0.0%)
|
0 (0.0%)
| |
|
ALT
| | |
0.655
|
|
(1&2)
|
2 (15.4%)
|
3 (23.1%)
| |
|
(3&4)
|
0 (0.0%)
|
0 (0.0%)
| |
|
AST
| | |
0.157
|
|
(1&2)
|
2 (15.4%)
|
0 (0.0%)
| |
|
(3&4)
|
0 (0.0%)
|
0 (0.0%)
| |
|
GGT
| | |
1.000
|
|
(1&2)
|
1 (7.7%)
|
1 (7.7%)
| |
|
(3&4)
|
0 (0.0%)
|
0 (0.0%)
| |
|
Dermatitis
| | |
0.414
|
|
(1&2)
|
8 (61.5%)
|
11 (84.6%)
| |
|
(3&4)
|
0 (0.0%)
|
0 (0.0%)
| |
|
Rash
| | |
0.655
|
|
(1&2)
|
3 (23.1%)
|
2 (15.4%)
| |
|
(3&4)
|
0 (0.0%)
|
0 (0.0%)
| |
|
Mucositis
| | |
0.093
|
|
(1&2)
|
5 (38.5%)
|
8 (61.5%)
| |
|
(3&4)
|
7 (53.8%)
|
5 (38.5%)
| |
|
Taste change
| | |
1.000
|
|
yes
|
13 (100%)
|
13 (100%)
| |
|
no
|
0 (0.0%)
|
0 (0.0%)
| |
|
Vomit
| | |
0.046*
|
|
only nausea
|
6 (46.2%)
|
3 (23.1%)
| |
|
Nausea and vomit
|
2 (15.4%)
|
10 (76.9%)
| |
|
Weight loss
| | |
0.305
|
|
(1&2)
|
8 (61.6%)
|
7 (53.8%)
| |
|
(3&4)
|
3 (23.1%)
|
5 (38.5%)
| |
- Abbreviations: RT radiotherapy, h-R3/RT nimotuzumab and radiotherapy, CDDP/RT cisplatin and radiotherapy
- *All p values were obtained using the paired rank sum test
